Health Care & Life Sciences » Biotechnology | Theratechnologies Inc.

Theratechnologies Inc. | Balance Sheet

Fiscal year is December-November. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,172.00
3,304.00
15,682.00
8,318.00
24,507.00
64,724
Total Accounts Receivable
489.00
2,359.00
4,601.00
6,710.00
9,737.00
14,560
Inventories
10,995.00
10,618.00
12,705.00
12,265.00
9,339.00
14,736
Other Current Assets
404.00
1,173.00
1,430.00
1,129.00
1,012.00
3,831
Total Current Assets
13,060.00
17,454.00
34,418.00
28,422.00
44,595.00
97,851
Net Property, Plant & Equipment
281.00
146.00
111.00
47.00
62.00
135
Total Investments and Advances
11,287.00
-
-
3,900.00
9,866.00
6,913
Intangible Assets
-
15,054.00
15,554.00
20,605.00
21,772.00
42,818
Other Assets
216.00
-
-
-
-
-
Total Assets
24,844.00
32,654.00
50,083.00
52,974.00
76,295.00
147,717
ST Debt & Current Portion LT Debt
-
3,682.00
4,391.00
4,665.00
4,676.00
Accounts Payable
508.00
1,824.00
3,145.00
3,114.00
6,968.00
Other Current Liabilities
4,142.00
5,808.00
9,316.00
7,654.00
16,986.00
Total Current Liabilities
4,650.00
11,314.00
16,852.00
15,433.00
28,630.00
Long-Term Debt
-
13,470.00
12,505.00
8,902.00
4,543.00
Other Liabilities
1,666.00
2.00
702.00
1,748.00
-
Total Liabilities
6,316.00
24,786.00
30,059.00
26,083.00
33,173.00
Common Equity (Total)
18,528.00
7,868.00
20,024.00
26,891.00
43,122.00
Total Shareholders' Equity
18,528.00
7,868.00
20,024.00
26,891.00
43,122.00
Total Equity
18,528.00
7,868.00
20,024.00
26,891.00
43,122.00
Liabilities & Shareholders' Equity
24,844.00
32,654.00
50,083.00
52,974.00
76,295.00

About Theratechnologies

View Profile
Address
2015 Peel Street
Montréal Québec H3A 1T8
Canada
Employees -
Website http://www.theratech.com
Updated 07/08/2019
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). It offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montreal, Canada.